Sphera Funds Management Ltd. Inhibrx, Inc. Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $432,390 - $1.13 Million	-29,820 Reduced 11.63%	226,551 $8.61 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $3.25 Million - $5.43 Million	206,371 Added 412.74%	256,371 $4.7 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $848,000 - $1.39 Million	50,000 New	50,000 $1.3 Million
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $1.23 Million - $2.67 Million	-61,931 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $6.64 Million - $11.4 Million	-248,146 Reduced 80.03%	61,931 $2.71 Million

Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $3.05 Million - $4.57 Million	120,994 Added 63.99%	310,077 $10.3 Million
Q2 2021 Aug 17, 2021	BUY	$14.69 - $27.52 $1.09 Million - $2.05 Million	74,440 Added 64.93%	189,083 $5.2 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $1.16 Million - $2.95 Million	71,461 Added 165.49%	114,643 $2.3 Million
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $689,184 - $2.16 Million	43,182 New	43,182 $1.42 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.